| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, “[***]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028. |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The annual meeting of shareholders (the “Annual Meeting”) of Lineage Cell Therapeutics, Inc. (the “Company”), was held on June 10, 2026 and involved the election of directors of the Company and two other matters voted upon by the Company... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
CARLSBAD, CA – May 12, 2026 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its ... |
| 11 Mar 2026 |
8-K: Other Events
We have acted as counsel to Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), with respect to certain matters in connection with the offering by the Company of up to $60,000,000 (the “Shares”) of its common share... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 |
| 28 Nov 2025 |
8-K: Other Events
As previously reported, Lineage Cell Therapeutics, Inc. (the “Company”) applied for a Clinical Trial (CLIN2) award (the “CIRM Grant”) from the California Institute for Regenerative Medicine (“CIRM”) in June 2025 to support continued clin... |
| 24 Nov 2025 |
8-K: Other Events
As previously reported, in December 2021, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” the “Company,” or “Lineage”), entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the “Roche... |
| 12 Nov 2025 |
8-K: Other Events
On November 12, 2025, Lineage Cell Therapeutics, Inc. (the “Company”) sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under its at-the-market offering program. The ... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
CARLSBAD, CA – November 6, 2025 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, toda... |
| 26 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
CARLSBAD, CA – August 26, 2025 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalm... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
CARLSBAD, CA – August 12, 2025 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalm... |
| 02 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
As described under Item 5.07 below, at the annual meeting of shareholders (the “Annual Meeting”) of Lineage Cell Therapeutics, Inc. (the “Company”) held on June 26, 2025, the Company’s shareholders approved an amendment (the “EIP Amendme... |
| 23 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site |
| 09 Jun 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Lineage Cell Therapeutics, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements conce... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to be featured June 21st at Clinical Trials at the Summit 2025 |
| 01 May 2025 |
8-K: Other Events
Lineage Cell Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) has successfully completed a production run for two different product candidates, each produced from a customized, two-tiered current Good Manufacturing Practice (“cGM... |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
Positive 24 Month Visual Acuity Data with OpRegen® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit |
| 27 Jan 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure +1 more
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Broadwood Partners L.P. or its assigns (the “Holder”) is entitled, upon the terms and conditions hereinafter set forth, at any time on or after May 21... |
| 20 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2024, between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each,... |
Loading...